Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 68.16M P/E - EPS this Y -9.70% Ern Qtrly Grth -
Income -30.83M Forward P/E -1.09 EPS next Y -14.60% 50D Avg Chg 7.00%
Sales - PEG -0.01 EPS past 5Y - 200D Avg Chg 30.00%
Dividend N/A Price/Book 1.64 EPS next 5Y 47.60% 52W High Chg -28.00%
Recommedations 2.00 Quick Ratio 6.29 Shares Outstanding 27.11M 52W Low Chg 155.00%
Insider Own 11.81% ROA -36.95% Shares Float 22.44M Beta -
Inst Own 19.88% ROE -78.56% Shares Shorted/Prior 17.96K/18.11K Price 2.66
Gross Margin - Profit Margin - Avg. Volume 192,627 Target Price 6.00
Oper. Margin - Earnings Date Jul 29 Volume 191,557 Change -5.18%
About Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galecto, Inc. News
05/01/24 Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
02/14/24 Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
01/09/24 What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
12/30/23 Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
12/21/23 Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
10/23/23 Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
09/28/23 Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls
09/26/23 Galecto Announces Plans to Explore Strategic Alternatives
08/31/23 Galecto to Present at Investor Conferences in September
08/17/23 OrbiMed Advisors LLC Reduces Stake in Galecto Inc
08/17/23 Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
08/16/23 Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
08/15/23 Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
07/31/23 Galecto Reports Second Quarter Operating and Financial Results
07/25/23 These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
06/20/23 Galecto Set to Join Russell Microcap® Index
05/30/23 Galecto to Present at the Upcoming Jefferies Healthcare Conference
05/23/23 Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
05/20/23 Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky
05/17/23 Galecto to Present Poster at Upcoming ATS 2023 International Conference
GLTO Chatroom

User Image Capitulation_0 Posted - 1 day ago

$GLTO getting more interest as of late.. hmm

User Image Investor1337 Posted - 1 day ago

$GLTO :)

User Image sixmilliondollarman Posted - 2 days ago

$GLTO 👇a recent position I held. Open link and click on Background of Merger (p.30-35). Interesting read on how acquisitions go down. LABP had been in talks w AbbVie for 2 yrs about possible licensing. Then they turned to negotiations for takeover. That process took 6 months. GLTO has also been in licensing talks for some time prior to SA. Jeffries was the banker for LABP and also has a relationship with GLTO 🤷‍♂️ https://www.sec.gov/Archives/edgar/data/1785345/000119312524114268/d752872ddefm14a.htm

User Image Capitulation_0 Posted - 2 days ago

$GLTO if they can pull off $AGEN... hmm

User Image Capitulation_0 Posted - 2 days ago

$GLTO P2 dosing.. R/S and keep going? Raise funds and keep the lights on?

User Image Bionco Posted - 2 days ago

$GLTO someone is buying

User Image skyrockets_Inc Posted - 2 days ago

$GLTO I find it strange they are announcing trial updates when they are in strategic alternatives , could they be just continuing business as usual and not selling or RMing?

User Image Bionco Posted - 3 days ago

$GLTO I still believe some company will be interested in the potential of GB1211 in Oncology and Liver disease ... Patiently waiting for a deal. Or lose all my money here!

User Image Bionco Posted - 3 days ago

$GLTO Good news! First patient was dosed in NCI funded and investigator sponsored phase 2 trial of GB1211+k drug!

User Image mdrins00 Posted - 3 days ago

$GLTO Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma. GLOBENEWSWIRE 4:01 PM ET 5/1/2024

User Image Stock_Titan Posted - 3 days ago

$GLTO Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab https://www.stocktitan.net/news/GLTO/galecto-announces-first-patient-dosed-in-an-investigator-initiated-53mfq9sqblyl.html

User Image rockingrobert Posted - 3 days ago

$GLTO June 20, 2024 Annual Stockholders Meeting....one of the items on the agenda: To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company’s common stock at a ratio of not less than 1-for-4 and not greater than 1-for-25 (or any number in between), with the exact ratio, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors at any time within one year of the date of the Annual Meeting without further approval or authorization from the Company’s stockholders (the “Reverse Stock Split");

User Image makedatbread88 Posted - 04/30/24

$DNA $GLTO $APVO Beaten down bios on watch

User Image skyrockets_Inc Posted - 04/30/24

$GLTO 2 months left for deal to close for management to get their bonus. This is like watching paint dry at this point. I think RM is off the table at this point, not enough time. I think either asset sale/company sale/liquidation/ or continued financing. Let's see what happens.

User Image CEMBP_Trader Posted - 04/29/24

$GLTO The surface smells closer to some kind of financing than buyout or reverse merger 🤷‍♂️ Financing is generally bad for stock price price, but this is not in a typical situation by all means. Not sure what to think of it. Just saying.

User Image Bionco Posted - 04/29/24

$GLTO 10Q was filed https://www.sec.gov/ix?doc=/Archives/edgar/data/0001800315/000095017024049808/glto-20240331.htm

User Image sixmilliondollarman Posted - 04/29/24

$GLTO 👀 news any day! 👇Article gives an idea on deal complexity and time. Btw chairman of GLTO board with 4% stake Goldfischer was also board member/ shareholder of Epizyme https://www.fiercepharma.com/pharma/sec-filing-epizyme-details-its-desperate-days-free-fall-ipsen-deal

User Image i_jw Posted - 04/29/24

$GLTO Where are results? They were supposed to come April 26th? https://www.nasdaq.com/market-activity/stocks/glto/earnings#:~:text=Apr%2026%2C%202024-,Galecto%2C%20Inc.,a%20company's%20historical%20reporting%20dates.

User Image Bionco Posted - 04/28/24

$GLTO if it failed in strategic alternatives, GLTO would have to go with reverse split and then raise funds to develop its pipeline. My question is how can it find investors??

User Image Capitulation_0 Posted - 04/26/24

$GLTO R/S doesn't sound so bad.. look at AGEN.

User Image Capitulation_0 Posted - 04/26/24

$GLTO They've been silent for near 6 months. Time for updates.. I don't care what they decide to do at this point. I have just enough shares to be engaged but not enough to care what they do at this point.

User Image Capitulation_0 Posted - 04/26/24

$GLTO looks like Novo still has 2.5m shares.

User Image Bionco Posted - 04/25/24

$GLTO I hope that is the price if GLTO is dissolved in June 30 😂

User Image Investor1337 Posted - 04/25/24

$GLTO strange always ~ 0.7

User Image valorallure Posted - 04/24/24

$GLTO Still doing my DD on this one. Like that they announced strategic alternatives. GB1211 looks promising. Sells below net cash even after accounting for another year of cash burn. I'm not a fan of reverse mergers. Prefer asset sale or liquidation. I'm hoping since this company still has a viable drug, reverse merger is off the table. How do others feel about reverse mergers? How would you avoid this risk?

User Image skyrockets_Inc Posted - 04/23/24

$GLTO They typically release 1stQ earnings around this week in the past few years. Let's see if we get an update in next 10 days.

User Image Investor1337 Posted - 04/23/24

$GLTO wake up

User Image Riptank Posted - 04/19/24

$GLTO

User Image sixmilliondollarman Posted - 04/18/24

$GLTO 👀 reversed the last 8 closes. Closing above .73 is a change of character on daily chart. Then they go after the liquidity above the recent highs. But maybe SA news comes first 🤷‍♂️

User Image NotHopeJustFacts Posted - 04/18/24

$GLTO reverse split coming and people in here keep getting distracted by BS.... when RS, they will be wiped out, and will never recover their investment... is a fact

Analyst Ratings
HC Wainwright & Co. Neutral Sep 28, 23
HC Wainwright & Co. Buy Aug 21, 23
SVB Leerink Market Perform Aug 15, 23
Oppenheimer Outperform Aug 1, 23
HC Wainwright & Co. Buy Aug 1, 23
Oppenheimer Outperform Jun 20, 23
HC Wainwright & Co. Buy May 24, 23
HC Wainwright & Co. Buy May 15, 23
Cantor Fitzgerald Overweight Mar 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ORBIMED ADVISORS LLC 10% Owner 10% Owner Jul 31 Sell 3 209,400 628,200 2,105,909 08/02/23
ORBIMED ADVISORS LLC 10% Owner 10% Owner Jul 13 Sell 2.4 194,700 467,280 2,285,687 07/17/23
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 13 Sell 1.88 68,481 128,744 2,417,787 04/17/23
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 10 Sell 1.81 67,537 122,242 2,464,234 04/12/23
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 05 Sell 2.09 102,630 214,497 2,510,041 04/07/23
Lindmark Bertil Chief Medical Office.. Chief Medical Officer Mar 22 Buy 2.16 14,604 31,545 16,604 03/23/22
Schambye Hans T. Chief Executive Offi.. Chief Executive Officer Mar 22 Buy 2.15 5,000 10,750 52,428 03/23/22